Yang et al. (Yang et al. 2019) found that CD3+T and CD4+T cells are independent predictors of PFS and OS in metastatic breast cancer patients with different molecular phenotypes, but no predictive value is found for CD19+B cells in relation to prognosis, nor any association between CD19+B cells and clinical factors in breast cancer. This evidence concerns the gene CD4 and breast cancer.